A Huntington disease genetic test measures CAG repeats in HTT: 26 or fewer is normal, 27–35 intermediate, 36–39 reduced penetrance, and 40 or more full penetrance. Testing can investigate symptoms or predict inherited risk before symptoms, but the repeat count cannot give an exact onset age; predictive testing should begin with genetic counseling.
- Normal allele: 26 or fewer HTT CAG repeats is not associated with Huntington disease caused by the usual HTT expansion.
- Intermediate allele: 27–35 repeats is not expected to cause Huntington disease in the person tested, but transmission can sometimes produce a larger repeat.
- Reduced penetrance: 36–39 repeats can cause Huntington disease, although some carriers never develop recognizable symptoms during their lifetime.
- Full penetrance: 40 or more repeats is expected to cause Huntington disease if the person lives a normal lifespan; it does not establish that symptoms have already begun.
- Two allele counts: A result such as 18/42 reports two separate HTT alleles. Do not add them together or calculate their average.
- Inheritance: A parent with one Huntington-associated expansion generally has a 50% chance of passing that allele to each child.
- Onset uncertainty: Longer repeats tend to be associated with earlier onset across populations, but no repeat count provides an exact personal onset date.
- Testing purpose: Diagnostic testing investigates existing symptoms; predictive testing answers an inherited-risk question before clear symptoms.
- Counseling first: Predictive testing should include informed consent, psychological preparation, privacy discussions, and a planned results appointment.
What does a Huntington disease genetic test measure?
A Huntington disease genetic test measures the length of a repeated DNA sequence in the HTT gene. The clinically used categories are 26 or fewer repeats, 27–35, 36–39, and 40 or more; these categories describe the allele, not the person's current neurological condition.
CAG stands for the DNA bases cytosine, adenine, and guanine, arranged as a repeating three-base unit. This sequence contributes to a glutamine tract in huntingtin, but the laboratory reports repeat length—not huntingtin concentration in ng/mL and not a score of brain function.
Most people have 2 HTT alleles, one inherited from each biological parent, because HTT is located on chromosome 4. A targeted repeat-expansion assay usually examines DNA extracted from a laboratory sample; an ordinary full blood count or metabolic panel does not include this analysis.
My approach as Thomas Klein, MD, is to separate 3 questions before interpreting the report: what was measured, why testing was requested, and what decision the answer might change. The same expanded allele can support a diagnosis in a symptomatic person or identify future risk in someone currently well.
Kantesti is an AI blood test analyzer for explaining routine laboratory results, not a substitute for specialist HTT testing or pretest counseling. Our organizational background explains our role; even a clearly printed result of 42 repeats still needs a genetics-led conversation about its personal and family implications.
HTT CAG repeat interpretation: the four categories
HTT CAG repeat interpretation uses four established categories: normal at 26 or fewer, intermediate at 27–35, reduced penetrance at 36–39, and full penetrance at 40 or more. An expanded result is not an emergency solely because it crosses a numerical boundary.
The 36-repeat boundary marks the conventional beginning of Huntington-associated alleles, while 40 separates reduced from full penetrance. These boundaries summarize observed clinical and family data; they are not biological switches that make a 39-repeat allele harmless or a 40-repeat carrier symptomatic overnight.
The EMQN/CMGS laboratory guidance describes these categories and the safeguards needed for reliable repeat sizing (Losekoot et al., 2013). Near 35/36 or 39/40, ask whether the laboratory's validated sizing uncertainty could affect the category and whether clarification or additional analysis is appropriate.
A report can be both numerical and interpretive: 38 is a measured repeat length, while reduced penetrance is its clinical classification. Our explanation of qualitative versus quantitative reports helps distinguish the measurement from the conclusion without treating genetic results like routine reference-range flags.
These 4 categories apply to the reported HTT repeat, not to every inherited neurological disorder. If a person has progressive symptoms but neither allele is expanded, the appropriate next step is usually to revisit the neurological diagnosis and assay limitations—not to relabel a normal result as Huntington disease.
What do intermediate alleles of 27–35 repeats mean?
An intermediate HTT allele of 27–35 CAG repeats is not expected to cause classic Huntington disease in the person tested. Its main implication is reproductive: the repeat can occasionally expand during transmission, potentially entering a disease-associated range in a later generation.
Intermediate is not reduced penetrance. A hypothetical adult with 18/34 repeats should not be told that Huntington disease is likely or that subtle forgetfulness proves an early stage; the 34-repeat allele belongs to a different category from a 38-repeat allele.
Expansion risk is not identical throughout 27–35: alleles toward the upper end generally warrant more detailed reproductive discussion. Paternal transmission is more prone to expansion than maternal transmission, but family history, repeat structure, and the laboratory finding matter before anyone offers a numerical estimate.
A 50% chance of transmitting an intermediate allele is not a 50% chance that a child will develop Huntington disease. There are separate questions about inheritance, whether the repeat changes, and whether any resulting expansion is disease-associated; collapsing them into one percentage is a serious counseling error.
The category also differs from the uncertain health implications of common variants discussed in our MTHFR variant interpretation. For an intermediate HTT result, ask the genetics team to document the exact count, transmission considerations, and whether specialist reproductive counseling would help your particular family.
Why can 36–39 repeats have reduced penetrance?
Reduced penetrance at 36–39 HTT CAG repeats means that the allele can cause Huntington disease, but not every carrier develops recognizable disease during their lifetime. The term describes the probability of clinical expression—not a guarantee of mild symptoms if disease develops.
An asymptomatic person with 18/37 repeats has a Huntington-associated allele, but the report does not establish a current clinical diagnosis. Conversely, a person with compatible progressive neurological findings and 37 repeats should not have those findings dismissed merely because the allele is below 40.
A universal lifetime percentage for all 36–39 carriers would be misleading. Estimates vary with exact repeat length, age, how families were recruited, and how onset was defined; symptomatic families can make penetrance look higher than it does in less selected populations.
Age changes the remaining-risk question. Counseling a hypothetical 30-year-old with 38 repeats is not the same as counseling an 80-year-old with 38 repeats and no recognizable symptoms, even though the laboratory category is identical; the genetics team should distinguish lifetime estimates from risk over a specified future interval.
Do not equate a reduced-penetrance expansion with a common susceptibility variant such as those described in ApoE4 risk interpretation. Both require context, but their mechanisms and predictive meaning differ; HTT counts of 36–39 belong to an established disease-associated repeat-expansion category.
When is HTT testing diagnostic rather than predictive?
Diagnostic HTT testing investigates existing symptoms that a clinician considers compatible with Huntington disease. Progressive chorea, changes in coordination, cognitive decline, or behavioral changes may prompt evaluation, but isolated anxiety or occasional forgetfulness does not automatically make genetic testing diagnostic.
Consider a hypothetical 52-year-old with gradually increasing involuntary movements and impaired planning over 18 months. A neurologist would assess the movement pattern, medication history, cognition, and family history before interpreting an expanded HTT result; a positive molecular finding must still be related to the actual clinical presentation.
An absent family history does not completely exclude Huntington disease, even when testing identifies 40 or more repeats. Small families, adoption, early parental deaths, unrecognized diagnoses, and repeat changes between generations can obscure inheritance; the clinician should record what is genuinely known rather than assume the condition appeared without a family connection.
Cognitive symptoms often justify a memory-loss laboratory workup alongside neurological evaluation. Finding vitamin B12 deficiency or another treatable contributor does not erase a 42-repeat expansion, but it can change how much of the person's current difficulty is attributed to Huntington disease.
Medication effects and thyroid dysfunction can contribute to movement or behavioral symptoms; our thyroid test interpretation explains that separate assessment. Symptoms appearing abruptly over 1 day require urgent evaluation for acute causes, rather than waiting for a Huntington genetic test to explain them.
How does predictive testing differ before symptoms?
Predictive Huntington testing asks whether a person without clear diagnostic symptoms carries an HTT expansion. For an adult with an affected parent, testing can clarify an inherited risk often described as 50%, but deciding not to test—or postponing testing—is also a valid choice.
A hypothetical 28-year-old whose parent has a documented expansion may want information for family planning but not want an onset prediction. A good predictive-testing pathway identifies that distinction before sample collection, because the laboratory can answer the inheritance question more confidently than the timing question.
The recommendations by MacLeod et al. (2013) emphasize informed decision-making, counseling, and support around predictive testing. The process is not simply a DNA order: discussion should cover possible results, psychological readiness, family communication, confidentiality, and how the result will be delivered.
Predictive HTT testing is not equivalent to the routine prevention choices in our family-history screening decisions. A result of 41 repeats can reveal a serious future condition without defining when symptoms will begin, so a standard wellness consent form is not an adequate substitute.
A neurological assessment may be offered to clarify whether apparently asymptomatic testing is actually investigating early signs; protocols differ between centers. Before the first sample, agree on at least 2 practical details: who may receive the result and which clinician or counselor will be available immediately after disclosure.
How should you read two counts on an HTT report?
Most Huntington genetic test results report two HTT allele lengths, such as 18/42. Interpret each allele separately: the 42-repeat allele is full penetrance, while the 18-repeat allele does not cancel it, and the combined total of 60 has no standard diagnostic meaning.
Laboratories commonly use PCR with fragment sizing, with additional methods when needed to resolve an expansion or an ambiguous result. A single apparent allele can mean both copies have the same size, but technical limitations can sometimes obscure the second allele; an apparent 17/17 result needs the laboratory's own validated interpretation.
Large expansions, primer-binding differences, and allele dropout are reasons a laboratory may use supplementary testing. The 2013 EMQN/CMGS guidance discusses quality safeguards; a second specimen may also be requested for identity confirmation under local predictive-testing protocols, rather than because the repeat is expected to change between samples.
Kantesti is an AI lab test interpretation service for routine laboratory reports, not the laboratory that sizes HTT repeats. A result close to 35/36 should be clarified with the testing laboratory; automated transcription, a screenshot, or an online summary should never outrank the original signed report.
HTT repeat analysis is different from a chromosome-counting test, as our karyotype result interpretation explains. A normal karyotype does not exclude an HTT expansion, and routine exome sequencing may not reliably detect or size it; ask whether targeted repeat-expansion analysis was actually performed.
Why cannot a repeat count precisely predict symptom onset?
A Huntington disease repeat count cannot precisely predict onset because inherited repeat length is only one contributor to when clinical disease appears. People with the same count, including 42 repeats, can develop symptoms at different ages; a population association is not an individual appointment with disease.
Longer inherited repeats generally correlate with earlier onset, and very large expansions—often above 60 repeats—are associated with juvenile presentations. Neither observation creates a rigid cutoff: childhood disease can occur with smaller expansions, and a particular large count cannot identify an exact birthday when symptoms will start.
The Genetic Modifiers of Huntington's Disease Consortium (2019) showed that uninterrupted CAG length, rather than simply polyglutamine length, influences onset timing. CAA also encodes glutamine, so sequence interruptions can alter biological behavior without a simple change in protein tract length; a conventional repeat count may not fully describe that structure.
Repeats can also expand within some tissues over time, a process called somatic expansion, and DNA-maintenance genes influence this biology. A repeat measured from a routine laboratory sample is not a direct measurement of every brain cell; repeating a reported 43-repeat test annually is not an established way to monitor neurological progression.
Onset can mean the first psychiatric change, cognitive change, or clinically established motor syndrome—3 different endpoints. Our AI report source checks are relevant here: reject an online prediction that supplies one confident onset age without specifying its model, endpoint, uncertainty, and clinical limitations.
What should genetic counseling cover before testing?
Genetic counseling before predictive HTT testing should cover possible repeat categories, psychological readiness, family consequences, reproductive options, confidentiality, and the right not to know. Counseling is especially valuable because results from 27–35, 36–39, and 40 or more create different kinds of uncertainty.
A practical pretest conversation includes 4 possible outcomes, rather than just positive and negative. Someone prepared for a 42-repeat result may still find a 38-repeat reduced-penetrance result difficult, because it answers the inheritance question while leaving considerable uncertainty about whether disease will appear.
As Thomas Klein, MD, I would ask what support is available on the results day, not simply whether the person feels ready today. Severe untreated depression, active suicidal thoughts, or an acute crisis warrants immediate clinical attention and may justify postponing elective predictive testing; preparation should include at least 1 named support contact.
Genetic privacy concerns extend beyond the person tested because 1 result can reveal information about relatives. Insurance and employment protections differ by country and insurance type; seek local advice before elective testing if this affects your decision, without allowing insurance questions to delay medically necessary assessment of existing symptoms.
Before sharing sensitive files with Kantesti AI, review our privacy and data information and consider whether uploading a genetics report is necessary at all. Agree separately about clinician access, family access, and optional digital storage; consent to explain 2 routine laboratory results is not consent to disclose an inherited neurological finding.
How do inheritance and anticipation affect family risk?
Huntington disease follows autosomal dominant inheritance: a parent with one disease-associated HTT expansion generally has a 50% chance of passing that allele to each child. Anticipation describes earlier onset in a later generation, often related to repeat expansion during transmission, particularly through the father.
The 50% chance applies independently to each pregnancy. Having one child who inherits the expansion does not make the next child's chance lower, and having two children without it does not make the third child's chance higher; family outcomes do not balance themselves like a deck of cards.
Repeat length is not always copied unchanged between generations. A parent with 39 repeats and a child with 42 would fall into different penetrance categories, but those illustrative counts cannot be used as a forecast for another pregnancy; a genetics professional should explain the laboratory and family-specific evidence.
Inheritance counseling is also needed for other conditions, although their patterns differ, as discussed in our alpha-1 antitrypsin family risk article. For HTT, locating a relative's original confirmed report can be more useful than collecting several unverified descriptions of what relatives supposedly had.
Kantesti's Family Health Risk tools must not be used to turn an undocumented family story into a confirmed 50% HTT risk or an onset estimate. Our multigenerational consent guidance explains why each adult relative should control access to their own results; one person's disclosure does not authorize everyone's.
Should children be tested, and what are reproductive options?
Predictive testing of asymptomatic children for an adult-onset HTT expansion is generally deferred until they can make an informed decision as adults. Diagnostic testing is different: a child with concerning neurological symptoms may need specialist evaluation, especially when a large expansion above 60 repeats is clinically plausible.
Deferring predictive testing protects the child's future choice about knowing their genetic status. A 10-year-old with no symptoms does not gain a standard preventive treatment simply from learning an adult-onset HTT result, while the psychological and confidentiality consequences can last for years.
A symptomatic child should not be excluded from assessment because predictive testing is usually deferred. Juvenile Huntington disease can feature rigidity, slowness, seizures, or school-performance changes rather than typical adult chorea; age under 20 describes juvenile onset, not a separate genetic-test category.
Adults planning a family may discuss prenatal diagnosis or preimplantation genetic testing for monogenic disease, usually called PGT-M, through a specialist service. Where available, exclusion or nondisclosure approaches may allow reproductive planning without directly revealing the at-risk parent's own status, although arrangements and legal access vary substantially.
These are not decisions that an app should make for a family; our children's AI testing limits explain the broader safety boundary. Ask the genetics service to separate 3 issues clearly: the child's current health, the adult's right not to know, and the reproductive options actually available locally.
What should happen after Huntington genetic test results?
After Huntington genetic test results, follow-up should match the repeat category and the reason testing was performed. A symptomatic person with 40 or more repeats needs neurological care, while an asymptomatic carrier needs a planned support and follow-up discussion—not an automatic declaration that clinical disease has begun.
A specialist can establish a baseline of movement, cognition, mood, daily function, and family support. For a hypothetical person with 19/44 repeats who feels well, that baseline should be presented as a reference for future care, not a search for inevitable abnormalities at the first visit.
Depression deserves treatment whether the allele has 37 or 44 repeats, and it should not be dismissed as an unavoidable genetic consequence. Our low-mood laboratory assessment explains selected medical contributors; laboratory testing complements, rather than replaces, a mental-health assessment.
An unexpected intermediate or reduced-penetrance result may require another counseling appointment rather than an immediate management decision. If symptoms do not fit the finding—for example, progressive neurological changes with 18/32 repeats—ask whether the original diagnosis, sample identity, or assay limitations need review.
There is no diet or supplement established to remove an inherited 42-repeat HTT expansion. Clinical care can address symptoms and safety needs, and a specialist can discuss current research opportunities; seek urgent help for suicidal thoughts, sudden neurological changes, or serious swallowing difficulty rather than waiting for the next planned genetics visit.
Can AI interpret an HTT result or predict Huntington onset?
AI can help explain report terminology, but it cannot replace validated HTT laboratory analysis, clinical diagnosis, or predictive-test counseling. No explanation tool should turn a result of 41 repeats into a confident personal onset age or interpret an intermediate allele as established Huntington disease.
Kantesti is an AI blood test interpretation platform that supports understanding of routine laboratory findings; an HTT expansion requires a specialist genetics pathway. Our medical validation information describes the boundaries of evaluation, and those boundaries should not be stretched into a claim that AI can forecast disease from 38 repeats.
Kantesti AI cannot determine Huntington symptom onset from a repeat count. As Thomas Klein, MD, I would prioritize 3 checks when reviewing an explanation: does it preserve the laboratory category, distinguish predictive from diagnostic testing, and make its uncertainty visible rather than burying it after a frightening conclusion?
Transcription errors can materially change interpretation: misreading 35 as 36 changes the conventional category from intermediate to reduced penetrance. Our PDF transcription error checklist explains source checking; use the original report and do not submit sensitive genetic records merely to test an automated explanation.
A useful explanation should state both allele counts, the laboratory's conclusion, and any assay caveats without inventing missing details. If a report says 18/39, a tool should not round it to 40, average the alleles, or claim certainty about lifetime symptoms; discrepancies belong with the issuing laboratory and genetics team.
Research publications and the evidence behind CAG interpretation
The evidence for HTT CAG interpretation comes from Huntington-specific laboratory guidance, predictive-testing recommendations, and genetic research—not from routine blood chemistry publications. As of October 14, 2026, the 26, 35, 39, and 40 boundaries described here remain the conventional categories used in specialist interpretation.
Three external medical references support this article's main claims: Losekoot et al. (2013) for molecular testing, MacLeod et al. (2013) for predictive testing, and the Genetic Modifiers of Huntington's Disease Consortium (2019) for repeat structure and onset biology. These sources answer different questions; none supplies a precise personal onset date.
Kantesti's educational publications listed below are 2 additional resources for routine laboratory literacy, not evidence for HTT penetrance or Huntington onset. The coagulation testing guide addresses clotting measurements, while the serum proteins guide addresses protein results; neither should be cited to support a CAG threshold.
A DOI identifies a deposited publication, but it does not by itself establish peer review or clinical guideline status. The 2 Zenodo references retain their supplied titles and DOI links; ResearchGate and Academia.edu links are discovery searches, not claims that verified copies are hosted on those services.
For the final interpretation, keep 3 documents together: the original laboratory report, the genetics team's explanation, and your agreed follow-up plan. Our medical content standards describe evidence expectations; our medical advisory board describes professional oversight, not individualized approval of your genetic result.
Frequently Asked Questions
What CAG repeat count is positive for Huntington disease?
An HTT allele with 36 or more CAG repeats is Huntington-associated, but the interpretation differs between 36–39 and 40 or more. Counts of 36–39 have reduced penetrance, meaning some carriers never develop recognizable disease during their lifetime. Counts of 40 or more have full penetrance, meaning disease is expected within a normal lifespan. An expanded result in someone without symptoms does not establish that clinical Huntington disease has already begun.
Does an intermediate Huntington allele mean I will get the disease?
An intermediate HTT allele of 27–35 CAG repeats is not expected to cause classic Huntington disease in the person tested. The main concern is that the repeat can sometimes expand during transmission to a child, particularly through paternal transmission and toward the upper end of the intermediate range. A 50% chance of passing on that allele is not a 50% chance that the child will develop Huntington disease. A genetic counselor can explain the exact count and the limits of family-specific risk estimates.
What does a Huntington test result of 38 repeats mean?
An HTT result of 38 CAG repeats is in the reduced-penetrance range of 36–39. The allele can cause Huntington disease, but the result does not guarantee that recognizable symptoms will develop during the person's lifetime. It also does not mean that any eventual disease will necessarily be mild. Interpretation depends on age, existing symptoms, family history, and the testing laboratory's report.
Can 42 CAG repeats predict the age Huntington symptoms start?
A result of 42 HTT CAG repeats cannot predict an exact symptom-onset age. Longer repeats generally correlate with earlier onset across populations, but people with the same count can develop symptoms at different ages. Repeat structure, somatic expansion, genetic modifiers, and the definition of onset contribute to that variation. An online calculator cannot replace a specialist discussion of uncertainty.
What is the difference between diagnostic and predictive Huntington testing?
Diagnostic Huntington testing investigates existing symptoms that a clinician considers compatible with the condition, while predictive testing asks about an HTT expansion before clear diagnostic symptoms. The same result, such as 18/42 repeats, can therefore serve different clinical purposes. Diagnostic interpretation combines the genetic finding with neurological assessment and consideration of other causes. Predictive testing should include pretest counseling, informed consent, psychological preparation, and a planned results appointment.
Can children have a Huntington disease genetic test?
Predictive testing of an asymptomatic child for an adult-onset HTT expansion is generally deferred until the young person can make an informed decision as an adult. Diagnostic testing may be appropriate when a child has concerning neurological symptoms and juvenile Huntington disease is being considered. Juvenile onset means symptoms begin before age 20, and large expansions, often above 60 repeats, are associated with these presentations without forming a strict cutoff. A pediatric neurology and genetics team should guide testing, consent, and support.
Can a normal blood test rule out Huntington disease?
A normal full blood count, metabolic panel, or thyroid test cannot rule out Huntington disease because these tests do not measure HTT CAG repeats. Huntington testing requires a targeted genetic assay, usually reporting 2 allele lengths. A reliable result with both alleles at 26 or fewer repeats does not support Huntington disease caused by the usual HTT expansion. Persistent neurological symptoms still require clinical assessment for other causes and, when appropriate, review of assay limitations.
Get AI-Powered Blood Test Analysis Today
Join over 2 million users worldwide who trust Kantesti for instant, accurate lab test analysis. Upload your blood test results and receive comprehensive interpretation of 15,000+ biomarkers in seconds.
📚 Referenced Research Publications
Klein, T., Mitchell, S., & Weber, H. (2026). aPTT Normal Range: D-Dimer, Protein C Blood Clotting Guide. Kantesti AI Medical Research.
Klein, T., Mitchell, S., & Weber, H. (2026). Serum Proteins Guide: Globulins, Albumin & A/G Ratio Blood Test. Kantesti AI Medical Research.
📖 External Medical References
Losekoot M et al. (2013). EMQN/CMGS best practice guidelines for the molecular genetic testing of Huntington disease. European Journal of Human Genetics.
MacLeod R et al. (2013). Recommendations for the predictive genetic test in Huntington's disease. Clinical Genetics.
Genetic Modifiers of Huntington's Disease Consortium (2019). CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset. Cell.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for diagnosis and treatment decisions.
E-E-A-T Trust Signals
Experience
Physician-led clinical review of lab interpretation workflows.
Expertise
Laboratory medicine focus on how biomarkers behave in clinical context.
Authoritativeness
Written by Dr. Thomas Klein with review by Dr. Sarah Mitchell and Prof. Dr. Hans Weber.
Trustworthiness
Evidence-based interpretation with clear follow-up pathways to reduce alarm.